


30 April 2021



**Re: Official Information Act Request – Prostate Specific Membrane Antigen (PSMA) PET-CT funded by DHB**

I refer to your Official Information Act request dated 12 April 2021 requesting the following information:

**Please can you advise whether PSMA (Prostate Specific Membrane Antigen) PET-CT is funded by the DHB or only available privately?**

The DHB provides funding for the completion of PET-CT through third party contracts with private providers.

**If publicly funded, please can you advise whether there are criteria that must be met. For example:**

- **For staging of high risk and unfavourable intermediate risk prostate cancer before definitive local therapy.**
- **For restaging of PSA recurrence ( $\geq 0.2$ ng/ml).**

There are no formal criteria for the use of PSMA PET CT as there are no regionally approved indications for the PSMA PET CT. Requests for PSMA are considered by the Regional Urology multidisciplinary meeting (MDM) to determine if treatment planning warrants the need for PETCT and If so, they are then referred for a PET CT which is funded by the DHB.

You are entitled to seek a review of the response by the Ombudsman under section 28(3) of the Official Information Act. Information about how to make a complaint is available at [www.ombudsman.parliament.nz](http://www.ombudsman.parliament.nz) or freephone 0800 802 602.

Please note that this response, or an edited version of this response, may be published on the Auckland DHB website.

Yours faithfully



Ailsa Claire, OBE  
Chief Executive